Clinical Trials | A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy

The University of Virginia is participating in a clinical research study for adults ages 18 and over, who have been diagnosed with PD-L1 Positive Metastatic Non-Small Cell Lung Cancer. The purpose of this study is to determine the safety and efficacy of Acasunlimab in combination with pembrolizumab compared to docetaxel in subjects who have been treated with both PD-1/PD-L1 inhibitor and platinum-containing chemotherapy in the past. Subjects will receive either Acasunlimab and pembrolizumab once every 6 weeks or Docetaxel every 3 weeks. If enrolled, you will continue to receive treatment unless your disease gets worse, you experience unacceptable side effects, or you reach the maximum treatment duration (when receiving Acasunlimab and pembrolizumab). There is no maximum treatment date for Docetaxel. This trial is expected to last up to 5 years, including a prescreening period, 2 years of treatment, 90 day follow up period, and a post treatment follow up period. Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance. Additional information can be found here: https://www.clinicaltrials.gov/study/NCT06635824 [email protected]